| 1 | 1 | | 1 of 2 |
|---|
| 2 | 2 | | HOUSE DOCKET, NO. 3104 FILED ON: 1/20/2023 |
|---|
| 3 | 3 | | HOUSE . . . . . . . . . . . . . . . No. 1085 |
|---|
| 4 | 4 | | The Commonwealth of Massachusetts |
|---|
| 5 | 5 | | _________________ |
|---|
| 6 | 6 | | PRESENTED BY: |
|---|
| 7 | 7 | | Jack Patrick Lewis |
|---|
| 8 | 8 | | _________________ |
|---|
| 9 | 9 | | To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General |
|---|
| 10 | 10 | | Court assembled: |
|---|
| 11 | 11 | | The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill: |
|---|
| 12 | 12 | | An Act to address barriers to HIV prevention medication. |
|---|
| 13 | 13 | | _______________ |
|---|
| 14 | 14 | | PETITION OF: |
|---|
| 15 | 15 | | NAME:DISTRICT/ADDRESS :DATE ADDED:Jack Patrick Lewis7th Middlesex1/19/2023James K. Hawkins2nd Bristol1/27/2023Joanne M. ComerfordHampshire, Franklin and Worcester1/30/2023Carol A. Doherty3rd Bristol1/31/2023Susannah M. Whipps2nd Franklin1/31/2023Lindsay N. Sabadosa1st Hampshire1/31/2023Mindy Domb3rd Hampshire2/1/2023David Paul Linsky5th Middlesex2/1/2023Vanna Howard17th Middlesex2/3/2023Sean Garballey23rd Middlesex2/8/2023Kay Khan11th Middlesex2/8/2023Colleen M. Garry36th Middlesex2/8/2023Steven Ultrino33rd Middlesex2/8/2023David Allen Robertson19th Middlesex2/8/2023Tram T. Nguyen18th Essex2/8/2023Christine P. Barber34th Middlesex2/9/2023James C. Arena-DeRosa8th Middlesex2/9/2023Michelle M. DuBois10th Plymouth2/13/2023 2 of 2 |
|---|
| 16 | 16 | | James Arciero2nd Middlesex2/16/2023Shirley B. Arriaga8th Hampden2/22/2023Simon Cataldo14th Middlesex2/23/2023Rebecca L. RauschNorfolk, Worcester and Middlesex2/23/2023Natalie M. Higgins4th Worcester3/7/2023Danielle W. Gregoire4th Middlesex3/10/2023James B. EldridgeMiddlesex and Worcester3/13/2023 1 of 2 |
|---|
| 17 | 17 | | HOUSE DOCKET, NO. 3104 FILED ON: 1/20/2023 |
|---|
| 18 | 18 | | HOUSE . . . . . . . . . . . . . . . No. 1085 |
|---|
| 19 | 19 | | By Representative Lewis of Framingham, a petition (accompanied by bill, House, No. 1085) of |
|---|
| 20 | 20 | | Jack Patrick Lewis and others for legislation to address barriers to HIV prevention medication |
|---|
| 21 | 21 | | healthcare coverage. Financial Services. |
|---|
| 22 | 22 | | The Commonwealth of Massachusetts |
|---|
| 23 | 23 | | _______________ |
|---|
| 24 | 24 | | In the One Hundred and Ninety-Third General Court |
|---|
| 25 | 25 | | (2023-2024) |
|---|
| 26 | 26 | | _______________ |
|---|
| 27 | 27 | | An Act to address barriers to HIV prevention medication. |
|---|
| 28 | 28 | | Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority |
|---|
| 29 | 29 | | of the same, as follows: |
|---|
| 30 | 30 | | 1 SECTION 1: (a) As used in this section, the following words shall have the following |
|---|
| 31 | 31 | | 2meanings, unless the context clearly requires otherwise:- |
|---|
| 32 | 32 | | 3 “HIV”, human immunodeficiency virus. |
|---|
| 33 | 33 | | 4 “HIV prevention drug”, any preexposure prophylaxis drug approved for the prevention of |
|---|
| 34 | 34 | | 5HIV by the federal Food and Drug Administration, including any ancillary or support health |
|---|
| 35 | 35 | | 6service determined by the secretary of health and human services that is necessary to: (1) ensure |
|---|
| 36 | 36 | | 7that such a drug is prescribed or administered to a person who is not infected with HIV and has |
|---|
| 37 | 37 | | 8no medical contraindications to the use of such a drug; and (2) monitor such a person to ensure |
|---|
| 38 | 38 | | 9the safe and effective ongoing use of such a drug through: (A) an office visit; (B) laboratory |
|---|
| 39 | 39 | | 10testing; (C) testing for a sexually transmitted infection; (D) medication self-management and |
|---|
| 40 | 40 | | 11adherence counseling; (E) or any other health service specified as part of comprehensive HIV |
|---|
| 41 | 41 | | 12prevention drug services by the United States Department of Health and Human Services, the 2 of 2 |
|---|
| 42 | 42 | | 13United States Centers for Disease Control and Prevention or the United States Preventive |
|---|
| 43 | 43 | | 14Services Task Force. |
|---|
| 44 | 44 | | 15 (b)(1) Notwithstanding any general or special law to the contrary, any policy, contract or |
|---|
| 45 | 45 | | 16certificate of health insurance subject to chapters 32A, 118E, 175, 176A, 176B, 176G, 176I, 176J |
|---|
| 46 | 46 | | 17or 176Q of the General Laws that provides coverage for any HIV prevention drug shall not |
|---|
| 47 | 47 | | 18require: |
|---|
| 48 | 48 | | 19 (A) any cost-sharing, including co-payments or co-insurance, or any deductible; and |
|---|
| 49 | 49 | | 20 (B) prior authorization, step therapy or any other protocol that could restrict or delay the |
|---|
| 50 | 50 | | 21dispensing or provision of any HIV prevention drug. |
|---|
| 51 | 51 | | 22 (2) The commissioner of the division of insurance, in consultation with the secretary of |
|---|
| 52 | 52 | | 23health and human services, shall adopt any written policies, procedures or regulations necessary |
|---|
| 53 | 53 | | 24to implement this subsection. |
|---|